Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
BACKGROUND: Patients with influenza virus infection can develop severe pneumonia and acute respiratory distress syndrome (ARDS) which have a high mortality. Influenza virus infection is treated worldwide mainly by neuraminidase inhibitors (NAIs). However, monotherapy with NAIs is insufficient for se...
Main Authors: | Masaya Fukushi, Makoto Yamashita, Tohru Miyoshi-Akiyama, Shuku Kubo, Kenji Yamamoto, Koichiro Kudo |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3409853?pdf=render |
Similar Items
-
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
by: Christopher J Vavricka, et al.
Published: (2011-10-01) -
Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza
by: Toshiki Murasaka, et al.
Published: (2017-11-01) -
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
by: Takuro Mizuno, et al.
Published: (2014-01-01) -
Serial histopathological examination of the lungs of mice infected with influenza A virus PR8 strain.
by: Masaya Fukushi, et al.
Published: (2011-01-01) -
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
by: Takashi Azuma, et al.
Published: (2015-01-01)